- Conditions
- Left Ventricular Systolic Dysfunction, Sudden Cardiac Death
- Interventions
- regadenoson
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced May 22, 2026, 3:47 AM EDT